Compare DexCom, Inc. (DXCM) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Stanley Black & Decker, Inc. — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while Stanley Black & Decker, Inc. trades at $87.91 (market cap $13.67B). The key difference: DexCom, Inc. is far larger — about 2.1× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SWK | |
|---|---|---|
Market Cap | $28.06B | $13.67B |
Sector | Health | — |
52-Week High | $89.53 | $94.12 |
52-Week Low | $54.84 | $62.12 |
Enterprise Value | $27.03B | $19.84B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Stanley Black & Decker (SWK) trades at $90.11, up 3.14% today, with a neutral technical signal and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue trends show stability around $15B annually, while net income improved to $402M in 2025. Valuation metrics include a P/E of 36.05 and P/S of 0.88, with a dividend payout scheduled for June 2026.
SWK offers a turnaround story with earnings beats and cost-saving efforts, but faces headwinds from weak Tools & Outdoor demand and high debt. Analyst consensus is mixed with 43% buy ratings, a $82.75 price target below current levels, and risks including consumer sentiment and interest rate sensitivity. The stock's near-term direction hinges on Q2 earnings due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
